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following thalidomide withdrawal without tapering 
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Thalidomide (300-400 mg/day in divided doses) 
is highly effective in chronic, recurrent or severe 
erythema nodosum leprosum (ENL). Therapeu-
tic response is observed usually in ≥ 2 weeks after 
which it is tapered in 50 mg decrements every 2-4 
weeks to a lowest effective dose to maintain remis-
sion.1 We described here a case of severe ENL with 
vasculonecrotic ulcerations (we have used the term 
‘vasculonecrotic ENL’ here for such a phenom-
enon) which we feel was precipitated by sudden 
withdrawal of thalidomide without tapering doses.
This 65-year-old-HIV-negative-patient of 
ENL was taking multidrug therapy (WHO MDT-
MB) and prednisone in tapering doses for six 
months. He presented with fever, anemia, pedal 
edema, and multiple, erythematous papulo-nodu-
lo-pustular ENL. He had stopped all the drugs on 
his own a month back after initial improvement. 
Clinically he had tender ulnar, lateral popliteal and 
posterior tibial nerves, glove and stocking anes-
thesia, madarosis, infi ltrated earlobes, and 6+ BI. 
He had leukocytosis (24,000/mm3), neutrophilia 
(86%), and macrocytic anemia (hemoglobin 
4.6 g%). Serum biochemistry, G6PD estimation, 
blood and urine cultures, chest x-ray and urinaly-
sis were normal. Prednisone (60 mg/day), clofa-
zimine (100 mg three times/day), rifampicin 600 
mg once a month (of MDT-MB) and other sup-
portive treatment were re-prescribed. Dapsone 
was withheld in view of severe anemia. Thalido-
mide 300 mg was added after two weeks in view 
of inadequate control and prednisone was tapered 
to 40 mg/day. Two months later he was hospital-
ized with multiple painful large ulcers of varied 
size covered with necrotic slough over the extremi-
ties (Figure 1) and generalized multiple ENL le-
sions many with black eschars/crusts or pustules/
blisters. He was sick, febrile (temperature 100°F), 
had leg edema (extending up to lower abdomen), 
anemia and ulnar nerve neuritis (lateral popliteal 
and posterior tibial nerves were not palpable due 
to edema). He had stopped thalidomide for over a 
month due to its non-availability while continued 
taking the other drugs. Except for low hemoglobin 
(4 g%), leucocytosis (25,000/mm3) and neutro-
philia (84%), other lab investigations (includ-
Figure 1: Multiple, 1-10 cm sized, regular shaped, round/oval, deep and severe ulcers with necrotic slough, 
seen over (A) right inguinal area, and (B) leg. Similar ulcers were also present scattered over other body sites.
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ing wound-swab culture, serum biochemistry, and urinalysis) 
and systemic examination were normal. Histology revealed 
superfi cial and deep necrotizing vasculitis, features of lobular 
panniculitis/ENL and dermal necrosis, and numerous frag-
mented acid-fast bacilli on special staining. Treatment restart-
ed with prednisone (60 mg/day), clofazimine (100 mg three 
times/day), rifampicin (600 mg once a month), thalidomide 
(100 mg three times/day) and other supportive measures (in-
cluding blood transfusion for severe anemia). Wound care 
comprised surgical debridement of necrotic slough and daily 
antiseptic dressings. The lesions/ulcers showed involution 
in four weeks. He was discharged on prednisone 40 mg/day, 
thalidomide, clofazimine and rifampicin (in earlier doses). A 
month later repeat lab investigations were essentially normal 
and most of the ulcers had healed or showed healthy granula-
tion tissue/healing. Thalidomide was tapered off over the next 
two weeks. Other drugs and prednisone, tapered to 30 mg on 
alternated days, were continued without recurrences during 
eight-month of follow-up. 
DISCUSSION
The occurrence of ENL when prednisone is being tapered 
off is a well-known phenomenon and was observed in our 
patient as not so severe initial episode. Most of the clinico-
pathological features of vasculonecrotic ENL2,3 in our patient 
developed subsequently and apparently after stopping tha-
lidomide without tapering doses while being on prednisone/
clofazimine and resolved completely in four weeks after re-
institution of thalidomide. Several studies have recorded high 
relapse rates and ﬂ are-ups in patients of thalidomide treated 
for aphthous ulcers (AU), Behçet’s syndrome (BS), discoid 
lupus erythematosus (DLE), and even ENL3,4 upon its dis-
continuation. In a large multicenter, double-blind crossover 
study > 50% AU patients using thalidomide had complete 
resolution but relapsed on switching over to placebo.5 Hamza6 
observed complete resolution in a patient of BS and palmo-
plantar pustulosis treated with thalidomide 200 mg/day for 
two months followed by 100 mg/day for 12 months but dis-
continuation was associated with disease ﬂ are-ups which 
were controlled with restarting the drug. Similarly, 71% DLE 
patients relapsed after marked regression when thalidomide 
was stopped.7 Welsh et al.4 also treated a patient of ENL who 
had relapsed when thalidomide dose was decreased to 50 mg/
day. Although the exact mechanism of these relapses remains 
un-elucidated, they suggest that thalidomide has only a sup-
pressive effect. The benefi cial effect of thalidomide in ENL 
has been attributed to its ability to inhibit inﬂ ammatory cy-
tokines TNF-α, IFN-γ, vascular endothelial-derived growth 
factor (VEGF), and basic fi broblast growth factor (bFGF) in 
RNA processing.8 Additionally, it effectively controls various 
clinical manifestations of ENL perhaps due to normalizing 
effects on CD4/CD8 ratio, decrease dermal infi ltration of 
polymorphonuclear leukocytes and T-cells, and down regu-
lation of ICAM-1 and MHC class-I antigens expression on 
keratinocytes.8 Premature withdrawal of thalidomide without 
tapering doses perhaps causes a sudden spurt of these inﬂ am-
matory cytokines, reversal in CD4/CD8 ratio, and neutro-
phils-lymphocytes chemotaxis as a rebound phenomenon. 
In other words, there is catastrophic reversal of thalidomide 
induced suppression of inﬂ ammatory process manifesting 
clinically in severe vasculonecrotic ENL. However, the vali-
dation of such hypotheses will depend on further and more 
comprehensive studies.
The adequate characterization of such a phenomenon 
and to anticipate possibility of its occurrence in ENL cases is 
important particularly in view of thalidomide therapy now 
being used frequently. Due to the side effects of thalidomide, 
its irregular availability in many countries, and now the pos-
sibility of vasculonecrotic ENL, its indiscriminate use needs 
to be curtailed. Clofazimine and pentoxiphylline can be one 
of the options in such situations.4 Encouraging results have 
also been reported with addition of pulse dexamethasone and 
azathioprine in patients not responding to steroids alone.9 
Designation of such a phenomenon as Lucio’s phenomenon 
should also be avoided where corticosteroids or thalidomide 
are of controversial or no therapeutic value while these will 
dramatically resolve vasculonecrotic ENL. The nomenclature 
‘vasculonecrotic ENL’ for this form of severe ENL seems more 
appropriate. Nevertheless, our points of view are open to de-
bate. 
[Braz J Infect Dis 2011;15(1):90-91]©Elsevier Editora Ltda.
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